ReviewHepatology international2020
Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group.
Review in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- The Association Between Cytomegalovirus Infection and Kidney Damage in the Liver Transplant Setting.Viruses · 2024Article
- Review
- Maintenance immunosuppressive therapy in liver transplantation: results from CESIT study, an Italian retrospective cohort study.BMJ open · 2024Article
- Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group.Hepatology international · 2024Review
- Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT).Updates in surgery · 2024Review
- Liver Transplantation Reverses Hepatic Myelopathy in the Decompensated Phase of Cirrhosis: Case Report and Literature Review.Journal of clinical and translational hepatology · 2024Article
- Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.Cancers · 2024Article
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy.Frontiers in public health · 2024Article
- Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation.World journal of gastrointestinal surgery · 2023Article
- Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy.Journal of clinical medicine · 2023Article
- The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Mepolizumab treatment in a patient with previous liver transplantation: One year follow-up.Respiratory medicine case reports · 2023Article
- A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.Medicina (Kaunas, Lithuania) · 2022Article
- Liver transplantation during COVID-19: Adaptive measures with future significance.World journal of transplantation · 2022Review
- A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.Journal of hepatology · 2022Article
- Mitochondria and Cancer Recurrence after Liver Transplantation-What Is the Benefit of Machine Perfusion?International journal of molecular sciences · 2022Review
- Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.Journal of hepatology · 2022Article
- Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives.Biomedicines · 2022Review
- Differences by transplant type in stool multiplex PCR testing for acute diarrhea in post-solid organ transplantation.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is a well-recognized fact that implementing new guidelines in clinical practice may be difficult; therefore the Italian Society for Organ and Tissue Transplantation (SITO) set out to define practical immunosuppression tools for the management of liver transplantation patients. In 2017, an Italian Working Group of liver transplant experts and hepatologists issued a set of consensus statements along with evidence-based recommendations on the use of everolimus after liver transplantation. This article presents the evidence- and consensus-based algorithms developed within the Italian Working Group, which are aimed towards guiding clinicians in the selection of immunosuppressive regimens for the management of adult liver transplant recipients in real-life practice. The liver transplant recipient population, typically managed in clinical practice, was divided into the following categories: (1) standard patients; (2) critically ill patients; (3) patients with a specific etiology; (4) patients with hepatocellular carcinoma; (5) and patients with de novo malignancies. The algorithms are divided into two parts, according to the time from transplantation (0-3 months and > 3 months) and are discussed here along with relevant supporting literature, when available. Ultimately, it is hoped that the evidence- and consensus-based algorithms developed within the Italian Working Group, and presented here, contribute to simplify, personalize, and optimize immunosuppression of liver transplantation recipients in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.